TOTAL VOLUME:

$134.1b

24H VOL:

$141,541,542

24H TRANSACTIONS:

2,388,728,490

OPEN INTEREST:

$1,440,096,988

406,065

Markets across

30,522

events

MATCHED EVENTS:

2,692

PLATFORM COVERAGE:

5

Polymarket:

39%

VS.

Kalshi:

61%

BETA
Dashboards
Tour
All
What will Johnson & Johnson say during their next earnings call?
⌛Ending Soon
kalshi

What will Johnson & Johnson say during their next earnings call?

Volume:
$89,516

Procedure

 - Kalshi

Procedure - Kalshi

1W

News

Positive

Negative

Neutral

Hover marker for details

Vol.

·

Resolved Apr 14, 2026

Closed: Sep 30, 10:00 AM EST

kalshi

Kalshi

View
Join Kalshi and score $25 for your first trade.
Outcome
Trade
Chance %
Price
Spread
Liquidity
Volume
24h
7d
Open Interest
Ends in
Result
kalshi

Procedure

View
100%
Yes 100¢No 0¢
—
N/A
$8,995
N/A
N/A
$5,870
16h 40m
Yes
kalshi

Darzalex Faspro

100%
Yes 100¢No 0¢
—
N/A
$7,287
N/A
N/A
$4,832
16h 40m
Yes
kalshi

Halda Therapeutics

100%
Yes 100¢No 0¢
—
N/A
$7,151
N/A
N/A
$4,345
16h 40m
Yes
kalshi

Rybrevant

100%
Yes 100¢No 0¢
—
N/A
$6,388
N/A
N/A
$5,401
16h 40m
Yes
kalshi

Ottava

100%
Yes 100¢No 0¢
—
N/A
$3,910
N/A
N/A
$3,569
16h 40m
Yes
kalshi

Tariff

100%
Yes 100¢No 0¢
—
N/A
$3,610
N/A
N/A
$3,231
16h 40m
Yes
kalshi

Europe

100%
Yes 100¢No 0¢
—
N/A
$2,408
N/A
N/A
$1,939
16h 40m
Yes
kalshi

Carvykti

100%
Yes 100¢No 0¢
—
N/A
$2,207
N/A
N/A
$1,637
16h 40m
Yes
kalshi

China

100%
Yes 100¢No 0¢
—
N/A
$1,698
N/A
N/A
$1,364
16h 40m
Yes
kalshi

AI / Artificial Intelligence

0%
Yes 0¢No 100¢
—
N/A
$22,113
N/A
N/A
$13,341
16h 40m
No
kalshi

Administration

0%
Yes 0¢No 100¢
—
N/A
$7,256
N/A
N/A
$4,118
16h 40m
No
kalshi

Nipocalimab / Lupus

0%
Yes 0¢No 100¢
—
N/A
$4,886
N/A
N/A
$2,647
16h 40m
No
kalshi

Vaccine

0%
Yes 0¢No 100¢
—
N/A
$4,819
N/A
N/A
$3,221
16h 40m
No
kalshi

Litigation

0%
Yes 0¢No 100¢
—
N/A
$3,748
N/A
N/A
$1,263
16h 40m
No
kalshi

Trufill

0%
Yes 0¢No 100¢
—
N/A
$3,039
N/A
N/A
$2,095
16h 40m
No
Total markets: 15

Description

A pharmaceutical company holds its earnings call to report quarterly results and discuss performance of its drug portfolio, pipeline developments, and global market conditions.